Beacon Biosignals has expanded its strategic collaboration with Takeda to advance the development of sleep-based biomarkers and diagnostic tools for narcolepsy. Under the extended agreement, Beacon will deploy its FDA-cleared at-home EEG headband, Waveband™, and AI-driven analytics to accelerate the understanding of sleep patterns and brain activity in people with narcolepsy. The partnership builds on a previous 2024 collaboration, now set to run for several years.
Takeda is expected to leverage Beacon’s real-world clinical database to identify novel neurophysiological signals linked to narcolepsy, which could improve screening, shorten diagnosis times, and better stratify patients for therapeutic trials. Meanwhile, Beacon may earn up to US $109 million in combined data-license fees, development, regulatory, and commercial milestones, as well as equity participation.
Narcolepsy remains underdiagnosed, particularly type 1 (NT1), where orexin-producing neurons are lost. Symptoms often overlap with other sleep disorders, leading to long diagnostic delays. Beacon says its platform could reduce that burden by providing more precise and scalable tools for tracking brain function during sleep.
Beacon’s CEO, Dr. Jacob Donoghue, highlighted that the collaboration aligns with Beacon’s mission to make brain function measurable at scale and generate biomarkers that can guide CNS drug development. For Takeda, the expanded deal supports its efforts to develop next-generation therapies informed by objective sleep and brain metrics.
